drugset / Trial / NCT00480935

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

NCT00480935 ↗

NaSingle-groupOpen-labelTreatment

Summary

Study Hypothesis: Patients with local renal cell carcinoma who are treated neoadjuvantly with Sutent may show a radiologic response to the study drug (Sutent). The study is looking at the neoadjuvant (pre-surgery) administration of Sutent in patients with localized kidney cancer. The purpose of this research is also to evaluate both the safety and effectiveness of Sutent in this patient population.

Timeline

Start
2007-10
Primary completion
2011-10
Completion
2011-10

Outcome

Outcome not reported

Stopped (Enrollment): “poor recruitment”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 50 mg —

Indications